Survivorship in immune therapy: Assessing toxicities, body compositionĀ and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB
Eur J Cancer. 2020 135: 211-220

PMID: 32599411 · PMCID: PMC7374019 · DOI:10.1016/j.ejca.2020.05.005

MeSH Terms (18)

Aged Antineoplastic Agents, Immunological B7-H1 Antigen Body Composition Female Functional Status Humans Immune Checkpoint Inhibitors Male Middle Aged Neoplasms Nutritional Status Programmed Cell Death 1 Receptor Progression-Free Survival Quality of Life Retrospective Studies Survivors Time Factors

Connections (1)

This publication is referenced by other Labnodes entities: